Medigus Announces Exercise and Closing of Underwriter’s Over-Allotment Option
OMER, Israel, Jan. 19, 2021 - Medigus Ltd. (Nasdaq, TASE: MDGS), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced that the underwriter of its previously announced underwritten public offering has exercised, in full, their option to purchase an additional 548,960 ADSs at a price of $2.30 per ADS. Total gross proceeds to the Company from the offering, including the funds received from the prior closing and exercise of this option, are approximately $9.6 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The offering was made pursuant to an F-3 registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus and accompany registration statement relating to the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov.
Aegis Capital Corp. acted as sole bookrunner for the offering.
A copy of the final prospectus and accompanying registration statement relating to the offering may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at email@example.com, or by telephone at (212) 813-1010.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the company’s advanced technology, please visit www.medigus.com.